JP2024542633A - がん治療用ｃｄｋ４阻害剤 - Google Patents

がん治療用ｃｄｋ４阻害剤 Download PDF

Info

Publication number
JP2024542633A
JP2024542633A JP2024532158A JP2024532158A JP2024542633A JP 2024542633 A JP2024542633 A JP 2024542633A JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024532158 A JP2024532158 A JP 2024532158A JP 2024542633 A JP2024542633 A JP 2024542633A
Authority
JP
Japan
Prior art keywords
cancer
subject
bid
therapeutically effective
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532158A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542633A5 (https=
Inventor
タン リン タン
ヤン ジン
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2024542633A publication Critical patent/JP2024542633A/ja
Publication of JP2024542633A5 publication Critical patent/JP2024542633A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024532158A 2021-12-02 2022-11-29 がん治療用ｃｄｋ４阻害剤 Pending JP2024542633A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163285320P 2021-12-02 2021-12-02
US63/285,320 2021-12-02
US202263382346P 2022-11-04 2022-11-04
US63/382,346 2022-11-04
US202263383969P 2022-11-16 2022-11-16
US63/383,969 2022-11-16
PCT/IB2022/061525 WO2023100070A1 (en) 2021-12-02 2022-11-29 Cdk4 inhibitor for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2024542633A true JP2024542633A (ja) 2024-11-15
JP2024542633A5 JP2024542633A5 (https=) 2025-11-19

Family

ID=84440018

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532158A Pending JP2024542633A (ja) 2021-12-02 2022-11-29 がん治療用ｃｄｋ４阻害剤

Country Status (9)

Country Link
US (1) US20250041298A1 (https=)
EP (1) EP4440576A1 (https=)
JP (1) JP2024542633A (https=)
KR (1) KR20240112931A (https=)
AU (1) AU2022400308B2 (https=)
CA (1) CA3240993A1 (https=)
IL (1) IL312650A (https=)
MX (1) MX2024006678A (https=)
WO (1) WO2023100070A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
CN120981721A (zh) 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105828822B (zh) * 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
GEP20227433B (en) 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2020157709A1 (en) * 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
FI4181920T3 (fi) * 2020-07-15 2025-11-20 Pfizer Kat6-estäjämenetelmät ja yhdistelmät syövän hoitoon
AU2021325426A1 (en) * 2020-08-13 2023-03-09 Astellas Pharma Inc. Combination therapy
AU2021345531B2 (en) * 2020-09-15 2024-02-29 Pfizer Inc. Solid forms of a CDK4 inhibitor
JP2024505680A (ja) * 2021-02-05 2024-02-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法

Also Published As

Publication number Publication date
US20250041298A1 (en) 2025-02-06
MX2024006678A (es) 2024-06-19
CA3240993A1 (en) 2023-06-08
EP4440576A1 (en) 2024-10-09
AU2022400308A1 (en) 2024-05-16
AU2022400308B2 (en) 2026-02-12
TW202329970A (zh) 2023-08-01
IL312650A (en) 2024-07-01
KR20240112931A (ko) 2024-07-19
WO2023100070A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
CN108024541B (zh) 用于治疗癌症的方法
AU2022400308B2 (en) Cdk4 inhibitor for the treatment of cancer
JP2024001009A (ja) Ｐｉ３ｋ阻害剤であるｇｄｃ－００７７による癌の治療方法
JP2022504388A (ja) Ｐｉ３ｋアルファ阻害剤およびメトホルミンを用いたがんの処置方法
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
AU2021382148A9 (en) Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
JP2022544485A (ja) Ａｔｐ競合性ａｋｔ阻害剤、ｃｄｋ４／６阻害剤、およびフルベストラントを含む併用療法を使用した乳がんの処置
US20250127759A1 (en) Methods and dosing regimens comprising a cdk2 inhibitor for the treatment of cancer
AU2021227007A1 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
EP4301356A1 (en) Treatment of breast cancer with amcenestrant and palbociclib
CN118338901A (zh) 用于治疗癌症的cdk4抑制剂
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
RU2854294C2 (ru) Ингибитор cdk4 для лечения рака
KR20210121188A (ko) 아나스트로졸과 조합된 cdk4/6 억제제를 함유하는 조성물의 종양 질환 치료용 약제의 제조에서의 용도
WO2023281413A1 (en) Methods and dosing regimens comprising pf-06873600 for the treatment of cancer
Kim et al. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer
US20160331755A1 (en) Pharmaceutical Combinations
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
EP4704847A1 (en) Combination of capivasertib, a cdk4/6 inhibitor and fulvestrant for use in the treatment of breast cancer
JP2026514253A (ja) 乳がんの治療に使用するためのカピバセルチブ、ｃｄｋ４／６阻害剤、及びフルベストラントの組み合わせ
HK40066922A (zh) 使用包含atp竞争性akt抑制剂、cdk4/6抑制剂和氟维司群的组合疗法来治疗乳腺癌

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251111